InvestorsHub Logo
Followers 4
Posts 929
Boards Moderated 0
Alias Born 08/15/2006

Re: SF Wolf post# 958

Sunday, 02/19/2017 12:58:06 PM

Sunday, February 19, 2017 12:58:06 PM

Post# of 21540
SF:

Great post. Questionable for anyone to try to minimalize the compassionate use patients and say that we're only relying on mice studies.

By the way, from biggercapital on twitter, it's my understanding that there were 4 treated with compassionate-use, so 3 out 4 showed impressive results.

To follow up on your quote: "No other reports have ever shown comparable benefits in such severely demented patients", below is the text of the slide from the corporate presentation.

-----------------------------------------------------------------

Compassionate Use Patients: Overview
Bryostatin Compassionate Use Program:

Severe Alzheimer’s Disease
No other reports have ever shown comparable benefits in such severely demented patients — albeit in the absence of age-matched controls.

Patient 1 – 95 y/o male (JT) – disoriented, intermittent coma, non-verbal
Course: Became alert, attentive; remembered date, place, time; mind active, engaged, watching TV, requested to return to work.

Patient 2 – 38 y/o female (JS) – familial Early-Onset AD due to PSEN1 mutation, Non-verbal, drooling, unable to swallow (fed with gastrostomy), attention grossly impaired, spasticity, inability to move
Course: Return of some language and vocalization, swallowing, increased attentiveness to environment & persons, increased range of motion

Patient 3 – 76 y/o white ? (FC)
Course: MMSE: 2-3, improved to 10-12; recognizes, vocalizes words. ADCS-ADL-severity score: 18 improved to 33; hallucinations: reduced; Return of complex motor skills — e.g. swimming, billiards.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News